+41 91 682 20 40 info@elixi-int.com

Pfizer’s Herceptin (trastuzumab) biosimlar Trazimera has been approved by the European Comission.

Pfizer has announced the European Commission (EC) has approved TRAZIMERA,  a biosimilar to Herceptin  (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.  This approval follows the recommendation from…

Read More